Business Context and Reporting Period
This Form 8-K is a current report filed by Athira Pharma, Inc. (not Leonabio, Inc.) on March 18, 2022. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the appointment of Dr. Michael Panzara to the Board of Directors, effective immediately on March 18, 2022. Key details include:
- Dr. Panzara was appointed as a Class I director with a term expiring at the 2024 annual meeting of stockholders.
- Committee assignments have not yet been determined.
- There are no related-party transactions or special arrangements regarding his appointment.
- He will receive an initial stock option grant under the Company's standard compensation plan for non-employee directors.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The only forward-looking element is the expiration date of Dr. Panzara's director term.
Investor Verification Checklist
- Verify the correct registrant name is Athira Pharma, Inc. (Ticker: ATHA), not Leonabio, Inc.
- Confirm Dr. Michael Panzara's background and qualifications as a new Class I director.
- Review the standard compensation plan for non-employee directors referenced in the January 31, 2022, Form 8-K to understand the scope of the stock option grant.
- Check for subsequent filings regarding Dr. Panzara's committee assignments.